Result card

  • EFF9a: What are the overall benefits and harms of IVIG in health outcomes of patients with Mild Cognitive Impairment?
  • EFF9b: What are the overall benefits and harms of IVIG in health outcomes of patients with mild-to-moderate Alzheimer’s disease? Jump to
  • EFF9c: What are the overall benefits and harms of IVIG in health outcomes of patients with moderate-to-severe Alzheimer’s disease? Jump to
English

What are the overall benefits and harms of IVIG in health outcomes of patients with Mild Cognitive Impairment?

Authors: Luca Vignatelli, Luciana Ballini, Susanna Maltoni, Jelena Barbaric, Mirjana Huic, Pernilla Östlund.

Internal reviewers: Gerardo Atienza, Agnes Mannik

x

Vignatelli L et al. Result Card EFF9a In: Vignatelli L et al. Clinical Effectiveness In: Jefferson T, Cerbo M, Vicari N [eds.]. Use of Intravenous immunoglobulins for Alzeheimer’s disease including Mild Cognitive Impairment [Core HTA], Agenas - Agenzia nazionale per i servizi sanitari regionali ; 2015. [cited 31 October 2020]. Available from: http://corehta.info/ViewCover.aspx?id=267

What are the overall benefits and harms of IVIG in health outcomes of patients with mild-to-moderate Alzheimer’s disease?

Authors: Luca Vignatelli, Luciana Ballini, Susanna Maltoni, Jelena Barbaric, Mirjana Huic, Pernilla Östlund.

Internal reviewers: Gerardo Atienza, Agnes Mannik

The same methodology was used as described in section for the whole domain.

x

Vignatelli L et al. Result Card EFF9b In: Vignatelli L et al. Clinical Effectiveness In: Jefferson T, Cerbo M, Vicari N [eds.]. Use of Intravenous immunoglobulins for Alzeheimer’s disease including Mild Cognitive Impairment [Core HTA], Agenas - Agenzia nazionale per i servizi sanitari regionali ; 2015. [cited 31 October 2020]. Available from: http://corehta.info/ViewCover.aspx?id=267

What are the overall benefits and harms of IVIG in health outcomes of patients with moderate-to-severe Alzheimer’s disease?

Authors: Luca Vignatelli, Luciana Ballini, Susanna Maltoni, Jelena Barbaric, Mirjana Huic, Pernilla Östlund.

Internal reviewers: Gerardo Atienza, Agnes Mannik

The same methodology was used as described in section for the whole domain.

x

Vignatelli L et al. Result Card EFF9c In: Vignatelli L et al. Clinical Effectiveness In: Jefferson T, Cerbo M, Vicari N [eds.]. Use of Intravenous immunoglobulins for Alzeheimer’s disease including Mild Cognitive Impairment [Core HTA], Agenas - Agenzia nazionale per i servizi sanitari regionali ; 2015. [cited 31 October 2020]. Available from: http://corehta.info/ViewCover.aspx?id=267

References